Amundi
SUPN icon

Amundi’s Supernus Pharmaceuticals SUPN Stock Holding History

Amundi’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$556K Sell
10,763
-10,196
-49% -$519K ﹤0.01% 1510
2025
Q4 		$1.04M Buy
20,959
+10,855
+107% +$528K ﹤0.01% 1265
2025
Q3 		$488K Buy
10,104
+955
+10% +$38.5K ﹤0.01% 1337
2025
Q2 		$293K Buy
+9,149
New +$293K ﹤0.01% 1522

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Amundi's SUPN Position: Q1 2026 in Review

Amundi reduced its Supernus Pharmaceuticals (SUPN) stake by 49% in Q1 2026, selling an estimated $519K and leaving 10,763 shares worth $556K. The position accounts for ﹤0.01% of the portfolio, ranked #1510.

Amundi first reported a position in SUPN in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.04M in Q4 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Amundi held 10,763 shares of Supernus Pharmaceuticals worth $556K as of Q1 2026.
  • Amundi sold 10,196 Supernus Pharmaceuticals shares in Q1 2026, an estimated $519K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Amundi's portfolio in Q1 2026, its #1510 holding.
  • Amundi first reported a position in Supernus Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Amundi's Supernus Pharmaceuticals position peaked at $1.04M in Q4 2025.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Amundi's 13F filing for Q1 2026, filed 18 May 2026.